Tuberculosis control in those receiving genetically engineering biologic drugs in Chelyabinsk Region

Abstract

Objective: to summarize the experience in screening and monitoring of tuberculosis infection in individuals receiving genetically engineering biological drugs in Chelyabinsk Region for the period from 2014 to 2018.Subjects and methods. 372 patients were enrolled in the trial, women made 206 (55.4%), men – 166 (44.6%). The average age of patients was 43.85 ± 1.4 years with no differences by gender. Records of 372 patient's histories were analyzed, they contained information on 1,192 visits of patients referred for screening and monitoring of tuberculosis infection while being treated by genetically engineering biologic drugs.Results. The stages of implementation and the results of screening and monitoring for tuberculosis infection in those receiving therapy with genetically engineering biologic drugs were analyzed at the regional level for 2014-2018. A procedure was developed and introduced to be implemented by a physician for phthisiologic follow-up of patients receiving genetically engineering biologic drugs; indications for computed tomography, IGRA tests were determined, indications for preventive treatment were summarized.Conclusions. The experience presented in the organization of tuberculosis control those treated with genetic engineering immunobiological therapy allows disseminating a similar model to any region. To work with this “new risk group”, i.e. individuals receiving genetically engineering biologic drugs, it is advisable to concentrate such patients in a head tuberculosis control institution to generate statistical data, as well as to ensure the best results for the detection, diagnosis and treatment of tuberculosis in this category of patients.

Keywords

• генно-инженерные иммунобиологические препараты
• скрининг и мониторинг туберкулезной инфекции
• фтизиатрическое сопровождение